Well Referenced

Tag: GLP-1 receptor agonist

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The 2023 OASIS 1 trial evaluated the efficacy and safety of oral semaglutide 50 mg daily in 667 adults with overweight or obesity without type 2 diabetes. Over 68 weeks, participants receiving semaglutide experienced a mean weight loss of 15.1%, compared to 2.4% with placebo. Notably, 85% of the semaglutide

Read More »
June 26, 2025 No Comments

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial

This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or

Read More »
June 26, 2025 No Comments

Tirzepatide Once Weekly for the Treatment of Obesity

This 2022 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks in 2,539 adults with obesity or overweight with at least one weight-related comorbidity, excluding diabetes. Participants receiving tirzepatide experienced significant, dose-dependent weight reductions: −15.0% with

Read More »
June 26, 2025 No Comments

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

This 2022 mini-review discusses tirzepatide, a first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, approved for type 2 diabetes and obesity management. Tirzepatide significantly reduces glycemic levels, improves insulin sensitivity, and promotes weight loss exceeding 20%, along with favorable effects on lipid metabolism. Its design

Read More »
June 26, 2025 No Comments

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

This 56-week, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of 3.0 mg liraglutide in 3,731 overweight or obese adults without type 2 diabetes. Participants received daily subcutaneous injections of liraglutide or placebo, alongside lifestyle counseling. At week 56, the liraglutide group achieved a mean weight loss of 8.4

Read More »
June 26, 2025 No Comments

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

This 2015 randomized controlled trial investigated the effects of liraglutide, a GLP-1 receptor agonist, on leptin dynamics during weight loss maintenance in 52 healthy obese individuals. After achieving a 12% weight loss through a low-calorie diet, participants were randomized to receive liraglutide (1.2 mg/day) or no additional treatment for 52

Read More »
June 26, 2025 No Comments

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial

This 3-month, randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of exenatide, a GLP-1 receptor agonist, in 26 adolescents aged 12–19 years with severe obesity (BMI ≥1.2 times the 95th percentile or ≥35 kg/m²). Participants received lifestyle counseling and were randomized to exenatide (twice daily) or placebo. Exenatide

Read More »
June 26, 2025 No Comments